Julie Dechanet-Merville
Direktor/Vorstandsmitglied bei Lymphact - Lymphocyte Activation Technologies SA
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Diogo Remechido | M | - |
Lymphact - Lymphocyte Activation Technologies SA
 Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
| Martinho Tojo | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
| David Zeferino D'Azevedo Cristina | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
| Daniel Correia | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
| Bruno Silva-Santos | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
| Domenico Mavilio | M | - |
Lymphact - Lymphocyte Activation Technologies SA
Lymphact - Lymphocyte Activation Technologies SA BiotechnologyHealth Technology Lymphact - Lymphocyte Activation Technologies SA provides biotechnology solutions. It develops treatments for cancer and chronic viral diseases. The firm offers a technology platform that generates autologous and heterologous cellular immune therapies for clinical applications. The company was founded by Diogo Remechido in 2013 and is headquartered in Lisbon, Portugal. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Portugal | 6 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Julie Dechanet-Merville
- Persönliches Netzwerk
